Image Presentation
BibTex RIS Cite
Year 2024, Volume: 3 Issue: 3, 112 - 117, 27.09.2024
https://doi.org/10.5505/achmedj.2024.03016

Abstract

Effect of specific immunotherapy on plasma interleukin 13 and 8 levels in patients with allergic rhinitis

Year 2024, Volume: 3 Issue: 3, 112 - 117, 27.09.2024
https://doi.org/10.5505/achmedj.2024.03016

Abstract

Introductıon: This study aimed to evaluate interleukin (IL)-13 and IL-8 levels in patients with allergic rhinitis who were and were not receiving specific immunotherapy.
Methods: A total of 84 patients being followed up in the immunology-allergy outpatient clinic for allergic rhinitis (42 receiving immunotherapy) and 23 healthy control subjects were included. Serum IL-13 and IL-8 levels were measured by enzyme-linked immunosorbent assay in all groups.
Allergic rhinitis patients were also evaluated in terms of symptom scores, IgE levels, and skin prick test results.
Results: Comparison of serum IL-13 and IL-8 among the groups demonstrated that levels of both cytokines were significantly higher in both allergic rhinitis patient groups compared to controls (p<0.001), and significantly higher in symptomatic allergic rhinitis patients compared to patients receiving immunotherapy (p<0.001 for IL-13, p=0.004 for IL-8).
Conclusion: Immunotherapy is the only curative treatment for allergic rhinitis. The results of our study suggest that immunotherapy exerts its effect by modifying levels of IL-13 and IL-8 in addition to previously well-known cytokines.

There are 0 citations in total.

Details

Primary Language English
Subjects Traditional, Complementary and Integrative Medicine (Other)
Journal Section Research Articles
Authors

Gülşen Duman Talas This is me 0009-0001-6903-0051

Göksal Keskin 0000-0001-8553-5378

Publication Date September 27, 2024
Submission Date July 10, 2024
Acceptance Date September 25, 2024
Published in Issue Year 2024 Volume: 3 Issue: 3

Cite

EndNote Duman Talas G, Keskin G (September 1, 2024) Effect of specific immunotherapy on plasma interleukin 13 and 8 levels in patients with allergic rhinitis. ACH Medical Journal 3 3 112–117.